Irinotecan Pharmagen

Irinotecan, the active ingredient in Irinotecan Pharmagen, is a Topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It is employed in adult oncology patients to treat metastatic colorectal cancer, small cell lung cancer, and gastric cancer, often as part of combination chemotherapy regimens designed to improve response rates and survival.

GNH USA supplies Irinotecan Pharmagen as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, providing reliable sourcing, regulatory documentation and logistics support for global clinical and commercial use.

Irinotecan is a topoisomerase I inhibitor used in the treatment of several solid tumours. - Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine‑based chemotherapy. - Small cell lung cancer: incorporated into combination regimens for extensive‑stage disease. - Gastric cancer: administered in combination protocols for advanced disease.

Irinotecan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis: life‑threatening inflammation of the colon. - Hepatic toxicity: elevated liver enzymes or bilirubin indicating liver injury.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity. - Renal function: evaluate creatinine clearance and adjust if necessary. - Hepatic function: monitor liver enzymes and bilirubin levels. - Myelosuppression: perform regular complete blood counts to detect neutropenia or anemia. - Diarrhea: implement prophylactic loperamide and educate patients on early reporting. - Pregnancy: avoid use; safety in pregnancy is unknown. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan interacts with several drug classes that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce SN‑38 exposure and therapeutic effect. - Concurrent myelosuppressive agents: increase risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - UGT1A1 inhibitors (e.g., atazanavir): can raise SN‑38 levels and heighten toxicity. - Anticoagulants (e.g., warfarin): may require INR monitoring due to potential hepatic effects. - Proton pump inhibitors: may affect gastric pH and indirectly influence drug metabolism.